TFAM and urogenital neoplasm: In addition, miR-709 targets TFAM (mitochondrialtranscriptional factorA), a key factor in mitochondrial function.Inhibiting miR-709 reduces kidney injury and dysfunction in mice.These findings suggest that miR-709 is a potential target for AKItreatment.12